Literature DB >> 27025383

[Autoimmune pancreatitis: An update].

T Helmberger1.   

Abstract

CLINICAL/METHODICAL ISSUE: Autoimmune pancreatitis (AIP) is a rare disease, the pathophysiological understanding of which has been greatly improved over the last years. The most common form, type 1 AIP belongs to the IgG4-related diseases and must be distinguished from type 2 AIP, which is a much rarer entity associated with chronic inflammatory bowel disease. Clinically, there is an overlap with pancreatic cancer. Imaging and further criteria, such as serological and histological parameters are utilized for a differentiation between both entities in order to select the appropriate therapy and to avoid the small but ultimately unnecessary number of pancreatectomies. PERFORMANCE: The diagnostics of AIP are complex, whereby the consensus criteria of the International Association of Pancreatology have become accepted as the parameters for discrimination. These encompass five cardinal criteria and one therapeutic criterion. By applying these criteria AIP can be diagnosed with a sensitivity of 84.9%, a specificity of 100% and an accuracy of 93.8%. ACHIEVEMENTS: The diagnosis of AIP is accomplished by applying several parameters of which two relate to imaging. As for the routine diagnostics of the pancreas these are ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI). Important for the differential diagnosis is the exclusion of signs of local and remote tumor spread for which CT and MRI are established. The essential diagnostic parameter of histology necessitates sufficient sample material, which cannot usually be acquired by a fine needle biopsy. CT or MRI are the reference standard methods for identification of the optimal puncture site and imaging-assisted (TruCut) biopsy. PRACTICAL RECOMMENDATIONS: In patients presenting with unspecific upper abdominal pain, painless jaundice combined with the suspicion of a pancreatic malignancy in imaging but a mismatch of secondary signs of malignancy, AIP should also be considered as a differential diagnosis. As the diagnosis of AIP only partially relies on imaging radiologists also have to be aware of the clinical, serological and histological parameters for AIP in order to guide clinicians towards the correct diagnosis. Only in this way can the highly efficient steroid therapy be initiated and otherwise possibly severe forms of therapy be avoided.

Entities:  

Keywords:  Autoimmune disease; Idiopathic duct centric pancreatitis; IgG4 related disease; Lymphoplasmacytic sclerosing pancreatitis; Pancreatitis

Mesh:

Year:  2016        PMID: 27025383     DOI: 10.1007/s00117-016-0096-8

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  26 in total

1.  High serum IgG4 concentrations in patients with sclerosing pancreatitis.

Authors:  H Hamano; S Kawa; A Horiuchi; H Unno; N Furuya; T Akamatsu; M Fukushima; T Nikaido; K Nakayama; N Usuda; K Kiyosawa
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

Review 2.  Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis.

Authors:  K Yoshida; F Toki; T Takeuchi; S Watanabe; K Shiratori; N Hayashi
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

3.  Human cationic trypsinogen but not serine peptidase inhibitor, Kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis.

Authors:  Ming-Chu Chang; I-Shiow Jan; Po-Chin Liang; Yung-Ming Jeng; Ching-Yao Yang; Yu-Wen Tien; Jau-Min Wong; Yu-Ting Chang
Journal:  J Gastroenterol Hepatol       Date:  2014-12       Impact factor: 4.029

Review 4.  Recent advances in autoimmune pancreatitis: type 1 and type 2.

Authors:  Terumi Kamisawa; Suresh T Chari; Markus M Lerch; Myung-Hwan Kim; Thomas M Gress; Tooru Shimosegawa
Journal:  Gut       Date:  2013-06-08       Impact factor: 23.059

5.  Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience.

Authors:  Suresh T Chari; Thomas C Smyrk; Michael J Levy; Mark D Topazian; Naoki Takahashi; Lizhi Zhang; Jonathan E Clain; Randall K Pearson; Bret T Petersen; Santhi Swaroop Vege; Michael B Farnell
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07-14       Impact factor: 11.382

Review 6.  [Autoimmune pancreatitis].

Authors:  G Beyer; J Menzel; P-C Krüger; S Ribback; M M Lerch; J Mayerle
Journal:  Dtsch Med Wochenschr       Date:  2013-11-05       Impact factor: 0.628

Review 7.  Review of the diagnosis, classification and management of autoimmune pancreatitis.

Authors:  Derek A O'Reilly; Deep J Malde; Trish Duncan; Madhu Rao; Rafik Filobbos
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

8.  Unnecessary Procedures and Surgery in Autoimmune Pancreatitis.

Authors:  Christine N Manser; Christoph Gubler; Beat Müllhaupt; Peter Bauerfeind
Journal:  Digestion       Date:  2015-09-05       Impact factor: 3.216

9.  Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis.

Authors:  Phil A Hart; Terumi Kamisawa; William R Brugge; Jae Bock Chung; Emma L Culver; László Czakó; Luca Frulloni; Vay Liang W Go; Thomas M Gress; Myung-Hwan Kim; Shigeyuki Kawa; Kyu Taek Lee; Markus M Lerch; Wei-Chih Liao; Matthias Löhr; Kazuichi Okazaki; Ji Kon Ryu; Nicolas Schleinitz; Kyoko Shimizu; Tooru Shimosegawa; Roy Soetikno; George Webster; Dhiraj Yadav; Yoh Zen; Suresh T Chari
Journal:  Gut       Date:  2012-12-11       Impact factor: 23.059

10.  IgG4-related disease: dataset of 235 consecutive patients.

Authors:  Dai Inoue; Kotaro Yoshida; Norihide Yoneda; Kumi Ozaki; Takashi Matsubara; Keiichi Nagai; Kenichirou Okumura; Fumihito Toshima; Jun Toyama; Tetsuya Minami; Osamu Matsui; Toshifumi Gabata; Yoh Zen
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

View more
  3 in total

Review 1.  [Hepatopancreaticobiliary diseases in IgG4-associated autoimmune diseases].

Authors:  L Grenacher
Journal:  Radiologe       Date:  2016-12       Impact factor: 0.635

Review 2.  [Inflammatory and infectious abdominal peritoneal and mesenterial processes].

Authors:  A G Schreyer
Journal:  Radiologe       Date:  2018-01       Impact factor: 0.635

Review 3.  [IgG4-associated diseases : State of the art].

Authors:  A Kleger; T Seufferlein
Journal:  Radiologe       Date:  2016-12       Impact factor: 0.635

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.